About DeepVax
Fighting a global killer
Cancer is the second most likely cause of death today, and is estimated to be responsible for 9.6 million deaths annually (2018). Worldwide, about 1 in every 6 deaths is caused by cancer.
Existing cancer treatments are expensive, complex and usually damaging to the patient. They also have a variable degree of success – they are effective for some types of cancer and ineffective for others. Vaccines targeting cancer address all of these issues; extending lifespans, improving quality of life and making treatment available to a much higher proportion of the global population.
DeepVax: Targeting cancer with vaccines
DeepVax is a a research-based biomedical company founded in July 2018 and headquartered in Zurich, Switzerland.
DeepVax is primarily engaged in the discovery, development, manufacturing and marketing of innovative therapies for the treatment of cancer. DeepVax focuses on translational oncology research; more specifically on innovative personalized therapeutic cancer vaccines as well as immune-stimulators and immune-enhancer therapeutic cancer products.
Our Partners
DeepVax collaborates with a selection of academic and industrial partners on a number of projects. If you would like to work with us, or license our technology, please contact us.
